A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (INDUS-2)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized, Study to Evaluate the Efficacy and Safety of Two Doses of AUR101 in Patients With Moderate-to-Severe Psoriasis
Sponsor: Aurigene Discovery Technologies Limited
A PHASE2 clinical study on Chronic Plaque-type Psoriasis, this trial is completed. The trial is conducted by Aurigene Discovery Technologies Limited and has accumulated 8 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
-
May 2021 — Sep 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aurigene Discovery Technologies Limited
For direct contact, visit the study record on ClinicalTrials.gov .